{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:07:11Z","timestamp":1792260431635,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017751","name":"NIHR BioResource","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01NS093334"],"award-info":[{"award-number":["U01NS093334"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG053798"],"award-info":[{"award-number":["R01AG053798"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P20AG068053"],"award-info":[{"award-number":["P20AG068053"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG072959"],"award-info":[{"award-number":["P30AG072959"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R35AG71476"],"award-info":[{"award-number":["R35AG71476"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40120-023-00467-8","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T10:25:07Z","timestamp":1680690307000},"page":"727-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-9758","authenticated-orcid":false,"given":"Carla","family":"Abdelnour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Camila","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive G.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Aarsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"4","key":"467_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O\u2019Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673\u201383. https:\/\/doi.org\/10.1017\/S0033291713000494.","journal-title":"Psychol Med"},{"issue":"2","key":"467_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3233\/JAD-131856","volume":"41","author":"S Garcia-Ptacek","year":"2014","unstructured":"Garcia-Ptacek S, Farahmand B, Kareholt I, Religa D, Cuadrado ML, Eriksdotter M. Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry. J Alzheimers Dis. 2014;41(2):467\u201377. https:\/\/doi.org\/10.3233\/JAD-131856.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"467_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s1474-4422(17)30074-1","volume":"16","author":"C Mueller","year":"2017","unstructured":"Mueller C, Ballard C, Corbett A, Aarsland D. The prognosis of dementia with Lewy bodies. Lancet Neurol. 2017;16(5):390\u20138. https:\/\/doi.org\/10.1016\/s1474-4422(17)30074-1.","journal-title":"Lancet Neurol"},{"issue":"3\u20134","key":"467_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000358051","volume":"38","author":"R Oesterhus","year":"2014","unstructured":"Oesterhus R, Soennesyn H, Rongve A, Ballard C, Aarsland D, Vossius C. Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer\u2019s disease and Lewy body dementia. Dement Geriatr Cogn Disord. 2014;38(3\u20134):161\u20139. https:\/\/doi.org\/10.1159\/000358051.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"11","key":"467_CR5","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1212\/01.wnl.0000247041.63081.98","volume":"67","author":"MM Williams","year":"2006","unstructured":"Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67(11):1935\u201341. https:\/\/doi.org\/10.1212\/01.wnl.0000247041.63081.98.","journal-title":"Neurology"},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.dadm.2017.12.001","volume":"10","author":"C Mueller","year":"2018","unstructured":"Mueller C, Perera G, Rajkumar AP, et al. Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. Alzheimers Dement (Amst). 2018;10:143\u201352. https:\/\/doi.org\/10.1016\/j.dadm.2017.12.001.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"9","key":"467_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJMp2111320","volume":"385","author":"GD Rabinovici","year":"2021","unstructured":"Rabinovici GD. Controversy and progress in alzheimer\u2019s disease\u2014FDA approval of aducanumab. N Engl J Med. 2021;385(9):771\u20134. https:\/\/doi.org\/10.1056\/NEJMp2111320.","journal-title":"N Engl J Med"},{"issue":"11","key":"467_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/13543784.2019.1681398","volume":"28","author":"G Lee","year":"2019","unstructured":"Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Expert Opin Investig Drugs. 2019;28(11):951\u201365. https:\/\/doi.org\/10.1080\/13543784.2019.1681398.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"467_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s1474-4422(19)30153-x","volume":"19","author":"J-P Taylor","year":"2020","unstructured":"Taylor J-P, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157\u201369. https:\/\/doi.org\/10.1016\/s1474-4422(19)30153-x.","journal-title":"Lancet Neurol"},{"issue":"6","key":"467_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/13543784.2021.1916913","volume":"30","author":"ED Pope","year":"2021","unstructured":"Pope ED, Cordes L, Shi J, Mari Z, Decourt B, Sabbagh MN. Dementia with Lewy bodies: emerging drug targets and therapeutics. Expert Opin Investig Drugs. 2021;30(6):603\u20139. https:\/\/doi.org\/10.1080\/13543784.2021.1916913.","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"467_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40266-022-00939-w","volume":"39","author":"S MacDonald","year":"2022","unstructured":"MacDonald S, Shah AS, Tousi B. Current therapies and drug development pipeline in lewy body dementia: an update. Drugs Aging. 2022;39(7):505\u201322. https:\/\/doi.org\/10.1007\/s40266-022-00939-w.","journal-title":"Drugs Aging"},{"key":"467_CR12","doi-asserted-by":"publisher","unstructured":"Cummings J, Lee G, Nahed P, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295. https:\/\/doi.org\/10.1002\/trc2.12295","DOI":"10.1002\/trc2.12295"},{"issue":"4","key":"467_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JPD-229002","volume":"12","author":"K McFarthing","year":"2022","unstructured":"McFarthing K, Rafaloff G, Baptista M, et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2022 update. J Parkinsons Dis. 2022;12(4):1073\u201382. https:\/\/doi.org\/10.3233\/JPD-229002.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"467_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13195-022-01103-7","volume":"14","author":"JT O\u2019Brien","year":"2022","unstructured":"O\u2019Brien JT, Chouliaras L, Sultana J, et al. RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia\u2014an international Delphi consensus. Alzheimer\u2019s Res Therapy. 2022;14(1):169. https:\/\/doi.org\/10.1186\/s13195-022-01103-7.","journal-title":"Alzheimer's Res Therapy."},{"key":"467_CR15","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Accessed February 18, 2023. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"467_CR16","doi-asserted-by":"publisher","unstructured":"Fagiani F, Lanni C, Racchi M, Govoni S. Targeting dementias through cancer kinases inhibition. Alzheimers Dement (N Y). 2020;6(1):e12044. https:\/\/doi.org\/10.1002\/trc2.12044","DOI":"10.1002\/trc2.12044"},{"key":"467_CR17","doi-asserted-by":"crossref","unstructured":"Goldfine A, Faulkner R, Sadashivam V, et al. Results of a Phase 1 Dose-Ranging Trial, and Design of a Phase 2 Trial, of K0706, a Novel C-Abl Tyrosine Kinase Inhibitor for Parkinson\u2019s Disease. Neurology. 2019;92(15 Supplement):P2.8\u2013047.","DOI":"10.1212\/WNL.92.15_supplement.P2.8-047"},{"issue":"3","key":"467_CR18","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1212\/CPJ.0000000000000918","volume":"11","author":"KD Mahdavi","year":"2021","unstructured":"Mahdavi KD, Jordan SE, Barrows HR, et al. Treatment of dementia with bosutinib: an open-label study of a tyrosine kinase inhibitor. Neurol Clin Pract. 2021;11(3):e294\u2013302. https:\/\/doi.org\/10.1212\/CPJ.0000000000000918.","journal-title":"Neurol Clin Pract"},{"key":"467_CR19","doi-asserted-by":"publisher","unstructured":"Pagan FL, Torres-Yaghi Y, Hebron ML, et al. Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies. Alzheimers Dement (N Y). 2022;8(1):e12296. https:\/\/doi.org\/10.1002\/trc2.12296","DOI":"10.1002\/trc2.12296"},{"issue":"4","key":"467_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/jnr.24782","volume":"99","author":"CS Limegrover","year":"2021","unstructured":"Limegrover CS, Yurko R, Izzo NJ, et al. Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson\u2019s patient brain-derived alpha-synuclein. J Neurosci Res. 2021;99(4):1161\u201376. https:\/\/doi.org\/10.1002\/jnr.24782.","journal-title":"J Neurosci Res"},{"key":"467_CR21","unstructured":"Moebius H, Hua X, Church K, et al. Phase 1 study of NDX-1017: safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and dementia patients. J Prev Alzheimer\u2019s Dis. 2019;6(S22)"},{"issue":"8","key":"467_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/sj.gt.3303094","volume":"15","author":"D Takeuchi","year":"2008","unstructured":"Takeuchi D, Sato N, Shimamura M, et al. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther. 2008;15(8):561\u201371. https:\/\/doi.org\/10.1038\/sj.gt.3303094.","journal-title":"Gene Ther"},{"issue":"5","key":"467_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/1073858417748875","volume":"24","author":"R Balestrino","year":"2018","unstructured":"Balestrino R, Schapira AHV. Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist. 2018;24(5):540\u201359. https:\/\/doi.org\/10.1177\/1073858417748875.","journal-title":"Neuroscientist"},{"issue":"7","key":"467_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/s1474-4422(09)70146-2","volume":"8","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613\u20138. https:\/\/doi.org\/10.1016\/s1474-4422(09)70146-2.","journal-title":"Lancet Neurol"},{"issue":"10","key":"467_CR25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/s1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377. https:\/\/doi.org\/10.1016\/s1474-4422(10)70194-0.","journal-title":"Lancet Neurol"},{"key":"467_CR26","doi-asserted-by":"publisher","unstructured":"Cummings J, Bauzon J, Lee G. Who funds Alzheimer's disease drug development? Alzheimers Dement (N Y). 2021;7(1):e12185. https:\/\/doi.org\/10.1002\/trc2.12185","DOI":"10.1002\/trc2.12185"},{"issue":"1","key":"467_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40035-022-00299-w","volume":"11","author":"F Rodriguez-Porcel","year":"2022","unstructured":"Rodriguez-Porcel F, Wyman-Chick KA, Abdelnour Ruiz C, et al. Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Transl Neurodegener. 2022;11(1):24. https:\/\/doi.org\/10.1186\/s40035-022-00299-w.","journal-title":"Transl Neurodegener."},{"issue":"9","key":"467_CR28","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jagp.2013.01.072","volume":"22","author":"DR Lee","year":"2014","unstructured":"Lee DR, McKeith I, Mosimann U, et al. The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry. 2014;22(9):926\u201335. https:\/\/doi.org\/10.1016\/j.jagp.2013.01.072.","journal-title":"Am J Geriatr Psychiatry"},{"key":"467_CR29","doi-asserted-by":"publisher","unstructured":"Jiang Y, Alam JJ, Gomperts SN, et al. Preclinical and randomized clinical evaluation of the p38\u03b1 kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nature Communications. 2022;13(1)https:\/\/doi.org\/10.1038\/s41467-022-32944-3","DOI":"10.1038\/s41467-022-32944-3"},{"issue":"3","key":"467_CR30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/mds.28879","volume":"37","author":"K Biglan","year":"2022","unstructured":"Biglan K, Munsie L, Svensson KA, et al. Safety and efficacy of mevidalen in lewy body dementia: a phase 2, randomized. Placebo-Controlled Trial Mov Disord. 2022;37(3):513\u201324. https:\/\/doi.org\/10.1002\/mds.28879.","journal-title":"Placebo-Controlled Trial Mov Disord."},{"issue":"17","key":"467_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355. https:\/\/doi.org\/10.1212\/WNL.0000000000009323.","journal-title":"Neurology"},{"key":"467_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12814","author":"JB Toledo","year":"2022","unstructured":"Toledo JB, Abdelnour C, Weil RS, et al. Dementia with Lewy bodies: impact of co-pathologies and implications for clinical trial design. Alzheimers Dement. 2022. https:\/\/doi.org\/10.1002\/alz.12814.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"467_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-018-0356-0","volume":"10","author":"AJ Thomas","year":"2018","unstructured":"Thomas AJ, Mahin-Babaei F, Saidi M, et al. Improving the identification of dementia with Lewy bodies in the context of an Alzheimer\u2019s-type dementia. Alzheimers Res Ther. 2018;10(1):27. https:\/\/doi.org\/10.1186\/s13195-018-0356-0.","journal-title":"Alzheimers Res Ther."},{"issue":"6","key":"467_CR34","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s43441-021-00315-7","volume":"55","author":"CC Lu","year":"2021","unstructured":"Lu CC, Li XN, Broglio K, et al. Practical considerations and recommendations for master protocol framework: basket, umbrella and platform trials. Ther Innov Regul Sci. 2021;55(6):1145\u201354. https:\/\/doi.org\/10.1007\/s43441-021-00315-7.","journal-title":"Ther Innov Regul Sci."},{"key":"467_CR35","doi-asserted-by":"publisher","unstructured":"Thorlund K, Haggstrom J, Park JJ, Mills EJ. Key design considerations for adaptive clinical trials: a primer for clinicians. BMJ. 2018;360:k698. https:\/\/doi.org\/10.1136\/bmj.k698","DOI":"10.1136\/bmj.k698"},{"key":"467_CR36","unstructured":"Adaptive Designs for Clinical Trials of Drugs and Biologics. Guidance for industry (Food and Drug Administration) (2019)."},{"issue":"1","key":"467_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-022-01015-6","volume":"14","author":"J Cummings","year":"2022","unstructured":"Cummings J, Montes A, Kamboj S, Cacho JF. The role of basket trials in drug development for neurodegenerative disorders. Alzheimers Res Ther. 2022;14(1):73. https:\/\/doi.org\/10.1186\/s13195-022-01015-6.","journal-title":"Alzheimers Res Ther."},{"key":"467_CR38","doi-asserted-by":"publisher","unstructured":"D'Antonio F, Kane JPM, Ibanez A, et al. Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimers Dement (Amst). 2021;13(1):e12235. https:\/\/doi.org\/10.1002\/dad2.12235","DOI":"10.1002\/dad2.12235"},{"issue":"1","key":"467_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13195-020-00703-5","volume":"12","author":"JG Goldman","year":"2020","unstructured":"Goldman JG, Forsberg LK, Boeve BF, et al. Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimers Res Ther. 2020;12(1):137. https:\/\/doi.org\/10.1186\/s13195-020-00703-5.","journal-title":"Alzheimers Res Ther."},{"issue":"1","key":"467_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13195-019-0476-1","volume":"11","author":"B Peterson","year":"2019","unstructured":"Peterson B, Armstrong M, Galasko D, et al. Lewy body Dementia association\u2019s research centers of excellence program: inaugural meeting proceedings. Alzheimers Res Ther. 2019;11(1):23. https:\/\/doi.org\/10.1186\/s13195-019-0476-1.","journal-title":"Alzheimers Res Ther."},{"issue":"5","key":"467_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/(sici)1099-1166(200005)15:5<387::Aid-gps131>3.0.Co;2-9","volume":"15","author":"IG McKeith","year":"2000","unstructured":"McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry. 2000;15(5):387\u201392. https:\/\/doi.org\/10.1002\/(sici)1099-1166(200005)15:5%3c387::Aid-gps131%3e3.0.Co;2-9.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9247","key":"467_CR42","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/s0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. The Lancet. 2000;356(9247):2031\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(00)03399-7.","journal-title":"The Lancet"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00467-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T06:51:37Z","timestamp":1702191097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00467-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. CA postdoctoral fellowship is funded by the Susan and Charles Berghoff Foundation. LLG is funded by the Alzheimer\u2019s Society. JC is supported by NIGMS grant P20GM109025; NINDS grant U01NS093334; NIA grant R01AG053798; NIA grant P20AG068053; NIA grant P30AG072959; NIA grant R35AG71476; Alzheimer\u2019s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; and the Joy Chambers-Grundy Endowment. No funding or sponsorship was received for the publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing and\/or Editorial Assistance"}},{"value":"All authors contributed to the study conception and design. Material preparation and data collection were performed by Carla Abdelnour and Maria Camila Gonzalez. Analysis was performed by Carla Abdelnour. The first draft of the manuscript was written by Carla Abdelnour and Maria Camila Gonzalez, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Carla Abdelnour has received the Sue Berghoff LBD Research Fellowship, and honoraria as speaker from F. Hoffmann-La Roche Ltd, Zambon, Nutricia, Schwabe Farma Ib\u00e9rica S.A.U. She is member of the Board of Directors of the Lewy Body Dementia Association. Maria Camila Gonzalez has no conflicts of interest. Lucy L. Gibson has no conflicts of interest. Kathleen L. Poston has been funded by grants to conduct research from the Michael J Fox Foundation for Parkinson\u2019s Research, the Lewy Body Dementia Association, the Alzheimer\u2019s Drug Discovery Foundation, the Sue Berghoff LBD Research Fellowship, and the NIH. She is on the Scientific Advisory Board for Curasen, where she receives consulting fees and stock options. She is on the Scientific Advisory Board for Amprion, where she receives stock options. Clive G. Ballard has received consulting fees from Acadia pharmaceutical company, AARP, Addex pharmaceutical company, Eli Lily, Enterin pharmaceutical company, GWPharm, H.Lundbeck pharmaceutical company, Novo Nordisk pharmaceutical company, Novartis pharmaceutical company, Janssen Pharmaceuticals, Johnson and Johnson pharmaceuticals, Orion Corp pharmaceutical company, Otsuka America Pharm Inc, Sunovion Pharm. Inc, Suven pharmaceutical company, Roche pharmaceutical company, Biogen pharmaceutical company, Synexus clinical research organization and tauX pharmaceutical company. Jeffrey L. Cummings has provided consultation to Acadia, Actinogen, Alkahest, AlphaCognition, AriBio, Biogen, BioVie, Cassava, Cerecin, Corium, Cortexyme, Diadem, EIP Pharma, Eisai, GemVax, Genentech, Green Valley, GAP Innovations, Grifols, Janssen, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Resverlogix, Roche, Sage Therapeutics, Signant Health, Simcere, Sunbird Bio, Suven, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. Dag Aarsland has received research support and\/or honoraria from Evonik, DailyColors, Muhdo, Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, Sanofi, Roche Diagnostics, and GE Health, and served as paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly, Anavex, Cognetivity, Enterin, Acadia, Sygnature, Biogen, Cognetivity, EIP Pharma, and Acadia.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}